The Innovative Medicines Initiative (IMI)’s new €9 million project to combat AMR with big data and AI

The Innovative Medicines Initiative (IMI)’s new €9 million project to combat AMR with big data and AI

  • 15/11/2021

Vaccines and monoclonal antibodies (mAb) (molecules engineered to mimic the immune response towards harmful pathogens) can play an important role in the fight against antimicrobial resistance because they are not sensitive to the inevitable obsolescence of antimicrobials. No comprehensive data-driven tools are available until now to inform decisions about the most efficient use of vaccines, as well as mAbs, in the fight against antimicrobial resistance. Research and development of vaccines and mAbs against resistant pathogens has consequently suffered a lack of financial investment, therefore increasing the burden of AMR.

The Innovative Medicines Initiative 2 (IMI2) called to life PrIMAVeRa, which is a new European public private partnership aimed at developing an open-source, web-based platform combining mathematical models with an epidemiological repository (i.e., that stores data relating to health and economic outcomes). With the help of this database, policymakers will be able to make data-driven decisions regarding prioritization of specific vaccines and monoclonal antibodies, informing the strategic allocation of resources.

Read the full article here: https://www.euvaccine.eu/post/primavera-a-new-ambitious-project-to-demonstrate-how-vaccines-can-combat-antimicrobial-resistance